Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Neuropsychiatry Stories

2014-03-18 16:25:20

NEW YORK, March 18, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and a live Internet webcast at 4:30 p.m. Eastern Time on Tuesday March 25, 2014 to discuss the financial results for the fourth quarter and year ended December 31, 2013. To access the live conference call via phone, dial...

2014-03-10 08:29:24

NEW YORK, March 10, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations. Dr. Sanchez will report to Sharon Mates, Ph.D., CEO and Chairman of Intra-Cellular Therapies. Dr. Sanchez has over ten years of experience as a Wall Street...

2014-03-05 12:27:25

Minerva president Rogerio Vivaldi and board chairman Marc Beer leading strategy to advance pipeline of novel therapies targeting applications in neuropsychiatry. CAMBRIDGE, Mass., March 5, 2014 /PRNewswire/ -- Minerva Neurosciences, Inc., a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced the launch of the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate...

2014-02-26 16:28:49

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34(th) Annual Healthcare Conference on March 3, 2014 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Mates will provide a corporate overview and business update. The live and archived webcast of the company presentation can be accessed under "Events and Presentations" in the...

2014-02-07 16:24:17

Producing important findings in a short timeframe is the goal of this special grant program CHICAGO, Feb. 7, 2014 /PRNewswire/ -- Brain Research Foundation (BRF) announced three recipients of its 2014 Scientific Innovations Award program (SIAs) for researchers investigating novel pathways to detect, treat and better comprehend serious neural diseases such as Parkinson's and schizophrenia. "The innovation that these researchers bring to addressing the scientific understanding and...

2014-02-07 08:24:13

NEW YORK, Feb. 7, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the 16(th) Annual BIO CEO and Investor Conference on February 10, 2014 at 4:30 p.m. Eastern Time at the Waldorf Astoria New York. Dr. Mates is also scheduled to present in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on February 12th, 2014 at 08:50 a.m. Eastern Time also at...

2014-01-30 20:23:12

NEW YORK, Jan. 30, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (OTCQB: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today announced the pricing of an underwritten public offering of 6,142,000 shares of its common stock at a public offering price of $17.50 per share. In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the...

2013-12-19 20:21:44

NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that its common stock has been approved for quotation on the OTC Markets - OTCQB tier (OTCQB) under the symbol "ITCI", and is expected to begin trading on December 20, 2013. ABOUT INTRA-CELLULAR THERAPIES Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of...

2013-12-18 12:26:56

- Genetic mutations associated with schizophrenia shown to impact cognitive function in individuals without disease or intellectual disability REYKJAVIK, Iceland, Dec. 18, 2013 /PRNewswire/ -- deCODE genetics, a global leader in analyzing and understanding the human genome, reported today in the journal Nature that mutations associated with an increased risk of schizophrenia and autism also affect cognition in individuals without the disease or intellectual disability. The research...

2013-10-22 23:02:59

The Capital Institute for Neurosciences, part of Capital Health, Hopewell Township, New Jersey, launches new program to treat Alzheimer's disease and other cognitive disorders. Hopewell Township, New Jersey (PRWEB) October 22, 2013 The Capital Institute for Neurosciences (CIN) today announced it has launched a new program to treat Alzheimer’s disease and other cognitive disorders, providing specialized care as well as medical and social support for patients and their families. As...


Latest Neuropsychiatry Reference Libraries

Biological Psychiatry
2012-06-04 19:30:28

Biological Psychiatry is a peer-reviewed scientific journal established in 1969 and published twice monthly (1st and 15th) by Elsevier since 1985. It is the official journal of the Society of Biological Psychiatry. The journal also publishes an annual supplement which contains the abstracts from the annual meeting of the Society. The founding editor-in-chief was Joseph Wortis, who edited the journal from 1969 to 1992. As of May 2012, the editor-in-chief is John H. Krystal (Chair of the...

More Articles (1 articles) »